TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
23 February 2024 - 11:30PM
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a
conference call will be held on Wednesday, February 28, 2024, at
8:30 AM ET to discuss results for the fourth quarter and year-end
2023 and provide a business outlook for 2024. Michael S. Weiss,
Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call
1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.),
Conference Title: TG Therapeutics Fourth Quarter and Year End
Update Call. A live webcast of this presentation will be available
on the Events page, located within the Investors & Media
section, of the Company's website at www.tgtherapeutics.com. An
audio recording of the conference call will also be available for
replay at www.tgtherapeutics.com, for a period of 30 days after the
call.
TG Therapeutics will announce its financial results for this
period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICSTG Therapeutics is a fully
integrated, commercial stage, biopharmaceutical company focused on
the acquisition, development and commercialization of novel
treatments for B-cell diseases. In addition to a research pipeline
including several investigational medicines, TG Therapeutics has
received approval from the U.S. Food and Drug Administration (FDA)
for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients
with relapsing forms of multiple sclerosis, including clinically
isolated syndrome, relapsing-remitting disease, and active
secondary progressive disease, as well as approval by the European
Commission (EC) and the Medicines and Healthcare Products
Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with
RMS who have active disease defined by clinical or imaging features
in Europe and the United Kingdom, respectively. For more
information, visit www.tgtherapeutics.com, and follow us on X
(formerly Twitter) @TGTherapeutics and on LinkedIn.
CONTACT:
Investor Relations
Email: ir@tgtxinc.comTelephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option
6
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Sep 2023 to Sep 2024